Literature DB >> 29188862

Editorial: Collaborative Efforts to Prevent Alzheimer's Disease.

J Touchon1, J Rosenbaum, P Aisen, S Andrieu, M C Carrillo, M Ceccaldi, J-F Dartiques, H Feldman, A Gabelle, M Isaac, L J Fitten, R A Sperling, B Vellas, P Tariot, M Weiner.   

Abstract

Entities:  

Mesh：

Year:  2017        PMID： 29188862     DOI： 10.1007/s12603-017-0961-9

Source DB:  PubMed          Journal:  J Nutr Health Aging        ISSN： 1279-7707            Impact factor:   4.075


× No keyword cloud information.
  10 in total

1.  Editorial: Preventive Trials for Alzheimer's Diseases: The Multi-domain and the Targeted Therapies Approaches Will Have to Be Associated.

Authors:  J Lin; B Dong; B Vellas
Journal:  J Nutr Health Aging       Date:  2016       Impact factor: 4.075

2.  Barriers for Prevention and Prodromal AD Trials.

Authors:  R C Petersen
Journal:  J Prev Alzheimers Dis       Date:  2016

Review 3.  2014 Update of the Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception.

Authors:  Michael W Weiner; Dallas P Veitch; Paul S Aisen; Laurel A Beckett; Nigel J Cairns; Jesse Cedarbaum; Robert C Green; Danielle Harvey; Clifford R Jack; William Jagust; Johan Luthman; John C Morris; Ronald C Petersen; Andrew J Saykin; Leslie Shaw; Li Shen; Adam Schwarz; Arthur W Toga; John Q Trojanowski
Journal:  Alzheimers Dement       Date:  2015-06       Impact factor: 21.566

Review 4.  Paths to Alzheimer's disease prevention: from modifiable risk factors to biomarker enrichment strategies.

Authors:  S Lista; B Dubois; H Hampel
Journal:  J Nutr Health Aging       Date:  2015-02       Impact factor: 4.075

5.  Re-Engineering Alzheimer Clinical Trials: Global Alzheimer's Platform Network.

Authors:  J Cummings; P Aisen; R Barton; J Bork; R Doody; J Dwyer; J C Egan; H Feldman; D Lappin; L Truyen; S Salloway; R Sperling; G Vradenburg
Journal:  J Prev Alzheimers Dis       Date:  2016-03-04

6.  Cognitive and functional changes associated with Aβ pathology and the progression to mild cognitive impairment.

Authors:  Philip S Insel; Michael C Donohue; R Scott Mackin; Paul S Aisen; Oskar Hansson; Michael W Weiner; Niklas Mattsson
Journal:  Neurobiol Aging       Date:  2016-08-26       Impact factor: 4.673

7.  MAPT STUDY: A MULTIDOMAIN APPROACH FOR PREVENTING ALZHEIMER'S DISEASE: DESIGN AND BASELINE DATA.

Authors:  B Vellas; I Carrie; S Gillette-Guyonnet; J Touchon; T Dantoine; J F Dartigues; M N Cuffi; S Bordes; Y Gasnier; P Robert; L Bories; O Rouaud; F Desclaux; K Sudres; M Bonnefoy; A Pesce; C Dufouil; S Lehericy; M Chupin; J F Mangin; P Payoux; D Adel; P Legrand; D Catheline; C Kanony; M Zaim; L Molinier; N Costa; J Delrieu; T Voisin; C Faisant; F Lala; F Nourhashémi; Y Rolland; G Abellan Van Kan; C Dupuy; C Cantet; P Cestac; S Belleville; S Willis; M Cesari; M W Weiner; M E Soto; P J Ousset; S Andrieu
Journal:  J Prev Alzheimers Dis       Date:  2014-06

8.  The Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER): study design and progress.

Authors:  Miia Kivipelto; Alina Solomon; Satu Ahtiluoto; Tiia Ngandu; Jenni Lehtisalo; Riitta Antikainen; Lars Bäckman; Tuomo Hänninen; Antti Jula; Tiina Laatikainen; Jaana Lindström; Francesca Mangialasche; Aulikki Nissinen; Teemu Paajanen; Satu Pajala; Markku Peltonen; Rainer Rauramaa; Anna Stigsdotter-Neely; Timo Strandberg; Jaakko Tuomilehto; Hilkka Soininen
Journal:  Alzheimers Dement       Date:  2013-01-17       Impact factor: 21.566

9.  Endpoints for Pre-Dementia AD Trials: A Report from the EU/US/CTAD Task Force.

Authors:  B Vellas; R Bateman; K Blennow; G Frisoni; K Johnson; R Katz; J Langbaum; D Marson; R Sperling; A Wessels; S Salloway; R Doody; P Aisen
Journal:  J Prev Alzheimers Dis       Date:  2015-06

10.  Biomarkers and cognitive endpoints to optimize trials in Alzheimer's disease.

Authors:  Philip S Insel; Niklas Mattsson; R Scott Mackin; John Kornak; Rachel Nosheny; Duygu Tosun-Turgut; Michael C Donohue; Paul S Aisen; Michael W Weiner
Journal:  Ann Clin Transl Neurol       Date:  2015-03-21       Impact factor: 4.511
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.